The last patient included in the study has completed the final protocol follow-up visit. The first results of the study will be released before the end of the first half of 2023, after the database is frozen and the statistical analysis work is completed. This international, multicenter Phase II/III study […]
Other News
LivaNova Receives U.S. FDA 510(k) Clearance for Essenz Heart-Lung Machine for Cardiopulmonary Bypass Procedures
LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Essenz™ Heart-Lung Machine (HLM). With FDA clearance, LivaNova initiates the commercial launch of Essenz in the U.S. The Company also recently received approval for […]
Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
— Full results from ELPIS I trial published in European Heart Journal Open – — First patient to be randomized in Japan Aging-Related Phase 2 study in Q1 – — Conference call scheduled for 8:30 a.m. ET today — MIAMI, March 10, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) […]
CytoSorbents Reports Fourth Quarter and Full Year 2022 Results
Pivotal U.S. and Canada STAR-T Trial enrollment passes halfway mark. Positive sales momentum from Q4 2022 continues in Q1 2023 to date, with expectation of sales growth in 2023 PRINCETON, N.J., March 09, 2023 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive […]
Acutus Medical to Announce Fourth Quarter and Full Year 2022 Financial Results
CARLSBAD, Calif., March 09, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its fourth quarter and full year 2022 financial results on Thursday, March 16, 2023. In […]
89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 – – Feedback from FDA supports advancement of Phase 3 program for pegozafermin in SHTG; plan to initiate first of two SHTG Phase 3 trials in the second quarter of 2023 – – Published results […]
VESTECK, Inc. is pleased to announce the first in human use of several SUTURE-TIGHT devices
WEST CHESTER, Pa., March 9, 2023 /PRNewswire/ — VESTECK, Inc. Scientific Advisory Board members along with Key Opinion Leaders from around the world, successfully completed the first 3 in human cases with the “SUTURE-TIGHT”TM catheter. Dr. Dai Yamanouchi and Professor Dainis Krievins successfully performed the first two endovascular aortic aneurysm repair (EVAR) procedures utilizing the “SUTURE-TIGHT”TM catheter in Riga, […]
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
TN-201 IND Cleared in January; Plan to Begin Phase 1b Dosing in MYBPC3-associated HCM Patients in Third Quarter 2023 Dosing Commenced in Multiple-Ascending Dose Stage of First-In-Human Clinical Trial of TN-301; Data Anticipated in Second Half 2023 2022 Year End Cash and Investments of $204 Million; Runway to Fund Operations into […]
Cardio Diagnostics Holdings, Inc Announces Financing Agreement with Yorkville Advisors Global, LP of up to $11.2 Million
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (the “Company”) (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that it has entered into a securities purchase agreement (“Securities Purchase Agreement”) with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP (“Yorkville”), under which the Company agreed to […]
Acticor Biotech Successfully Completes a Capital Increase for a Total Gross Amount of 12.2 Million Euros, via the Issuance of 1,793,005 Shares
PARIS–(BUSINESS WIRE)–Regulatory News: Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Australia or Japan. This press release does not constitute an offering document and is for information purposes only. ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT – the “Company“), a clinical-stage biotechnology company […]



